WO2022231263A1 - 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 - Google Patents
잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 Download PDFInfo
- Publication number
- WO2022231263A1 WO2022231263A1 PCT/KR2022/005927 KR2022005927W WO2022231263A1 WO 2022231263 A1 WO2022231263 A1 WO 2022231263A1 KR 2022005927 W KR2022005927 W KR 2022005927W WO 2022231263 A1 WO2022231263 A1 WO 2022231263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- formula
- halogen
- xanthine oxidase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title abstract description 7
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 title abstract description 6
- 230000015572 biosynthetic process Effects 0.000 title abstract description 6
- 238000003786 synthesis reaction Methods 0.000 title abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000005580 one pot reaction Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 3
- 201000005569 Gout Diseases 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 150000002431 hydrogen Chemical group 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 229960003459 allopurinol Drugs 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FTSLZSHWVUNXLF-UHFFFAOYSA-N ethyl 1-(1h-indol-5-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=C(NC=C2)C2=C1 FTSLZSHWVUNXLF-UHFFFAOYSA-N 0.000 description 2
- VIRCPRQEXPNHOV-UHFFFAOYSA-N ethyl 1-(3-cyano-1h-indol-5-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=C(NC=C2C#N)C2=C1 VIRCPRQEXPNHOV-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a method for preparing a major intermediate for synthesizing a xanthine oxidase inhibitor, and more particularly, to a novel method for synthesizing the intermediate of Formula 3 in high yield without a separate separation process:
- R1 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl or phenyl;
- R2 is hydrogen; C 1 -C 7 alkyl unsubstituted or substituted by a substituent selected from halogen, C 3 -C 7 cycloalkyl and O-R 6 , wherein R 6 represents C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; or (wherein W represents O or S, R7 represents hydrogen or C 1 -C 4 alkyl, and n is an integer from 0 to 3);
- R3 is hydrogen, halogen or C 1 -C 7 alkyl
- R4 is -C(O)OR8 and R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl.
- Xanthine oxidase is known as an enzyme that converts hypoxanthine to xanthine and also formed xanthine to uric acid. Since uricase, which is present in most mammals, is absent in humans and chimpanzees, uric acid is known to be the last product of purine metabolism (S. P. Bruce, Ann. Pharm., 2006, 40, 2187). ⁇ 2194). Uric acid maintained at a high concentration in the blood causes various diseases, including gout as a representative example.
- gout is a disease caused by a high level of uric acid in the body, and refers to a condition in which uric acid crystals are accumulated in cartilage, ligaments, and surrounding tissues of the joint, causing severe inflammation and pain. Gout is a type of inflammatory joint disease, and its incidence has been steadily increasing over the past 40 years (N. L. Edwards, Arthritis & Rheumatism, 2008, 58, 2587-2590).
- the number of gout patients in the West increased by 200-300%, and it is mainly found in men. Obesity, aging, decreased renal function, and hypertension are considered to be the causes of this increase in gout patients. If you look at the incidence of gout, the level is about 1.4/1000, but this also shows different results depending on the level of uric acid. In other words, the incidence of gout was 0.5% in the group of patients with blood uric acid levels of 7.0 mg/dl or higher, whereas the incidence of gout was 5.5% in the group of patients with uric acid levels above 9.0 mg/dl (G. Nuki, Medicine, 2006, 34, 417-423).
- Allopurinol is known as a non-specific inhibitor of various enzymes involved in purine and pyrimidine metabolism, and has a Ki 700 nM for xanthine oxidase (Y. Takano et al., Life Sciences, 2005, 76, 1835-1847). . It is known that allopurinol is oxidized by xanthine oxidase and converted to oxypurinol, and this metabolite acts as a very strong inhibitor of xanthine oxidase.
- Korean Patent Publication No. 10-2011-0037883 discloses a novel compound of Formula 1 effective as a xanthine oxidase inhibitor:
- A is selected from the following substituents A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii and A-viii;
- J represents hydrogen, halogen, or C 1 -C 6 -alkyl substituted or unsubstituted by halogen
- X is O or S
- Z is C or N
- E represents hydrogen, halogen, cyano, nitro, substituted or unsubstituted C 1 -C 6 -alkyl, or substituted or unsubstituted C 1 -C 6 -alkoxy,
- Q is selected from the following substituents Q-i, Q-ii, Q-iii-1 to Q-iii-9,
- W represents O or S
- R7 represents hydrogen or substituted or unsubstituted lower alkyl
- n is an integer from 0 to 3
- R8 and R9 each independently represent hydrogen or lower alkyl, and m is an integer of 1 to 3);
- R10 and R11 each independently represent hydrogen, halogen, lower alkoxy or lower alkyl, and m is an integer of 1 to 3;
- R12 represents substituted or unsubstituted lower alkyl or aromatic, and n is an integer from 0 to 3;
- R13 and R14 each independently represent a substituted or unsubstituted lower alkyl, or may form a 3-7 membered heterocycle including N, and n is an integer of 0-3);
- R15 represents substituted or unsubstituted lower alkyl, and m is an integer of 1 to 3;
- R15 represents substituted or unsubstituted lower alkyl, and m is an integer of 1 to 3;
- Y represents hydrogen, halogen, substituted or unsubstituted linear, branched or cyclic saturated or unsaturated alkyl, substituted or unsubstituted C 1 -C 6 -alkoxy, substituted or unsubstituted aromatic, or heteroaromatic,
- G represents hydrogen or substituted or unsubstituted linear, branched or cyclic saturated or unsaturated alkyl.
- the above method has a problem that it is not preferable for mass synthesis in high yield because it includes several synthesis steps.
- an object of the present invention is to provide a suitable method for more efficiently mass-producing the compound of Formula 3, which is a key intermediate in the synthesis of an excellent xanthine oxidase inhibitor.
- R1 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl or phenyl;
- R2 is hydrogen; C 1 -C 7 alkyl unsubstituted or substituted by a substituent selected from halogen, C 3 -C 7 cycloalkyl and O-R 6 , wherein R 6 represents C 1 -C 4 alkyl; C 3 -C 7 cycloalkyl; or (wherein W represents O or S, R7 represents hydrogen or C 1 -C 4 alkyl, and n is an integer from 0 to 3);
- R3 is hydrogen, halogen or C 1 -C 7 alkyl
- R4 is -C(O)OR8 and R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl.
- the compound of Formula 3 is prepared by reacting the compound of Formula 2 with chlorosulfonyl isocyanate and triethylamine in an organic solvent.
- the organic solvent in the method is, for example, at least one selected from ethyl acetate, dimethylformamide (DMF), acetonitrile, acetone, tetrahydrofuran (THF), and dichloromethane. Can be used.
- dimethylformamide may be used instead of triethylamine (NEt 3 ) in the above method.
- -CONHSO 2 Cl is formed as an intermediate by using chlorosulfonyl isocyanate in the compound of Formula 2, and a cyano group is introduced using triethylamine or dimethylformamide without additional separation or purification process.
- the compounds can be prepared in a one-pot reaction.
- the preparation method of the present invention can mass-produce the compound of Chemical Formula 3 in high yield in one step in the same container in the same solvent system without separating an intermediate from the compound of Chemical Formula 2.
- 1-(1H-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester (20 g, 78.3 mmol) was dissolved in 80 ml of ethyl acetate (EtOAc), and then dissolved in 80 ml of ethyl acetate (EtOAc) at 0-5° C. in 20 ml of ethyl acetate. Diluted chlorosulfonyl isocyanate (chlorosulfonyl isocyanate, 12.20 g, 86.2 mmol) was slowly added.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (3)
- 하기 화학식 2의 화합물을 유기용매 하에서 클로로설포닐 이소시아네이트 및 트리에틸아민을 첨가하여 원-포트(one-pot) 반응하는 것을 포함하는 화학식 3의 화합물의 제조 방법:[화학식 2][화학식 3]상기 화학식에서,R1은 수소, 할로겐, C1-C7 알킬, C1-C7 알콕시-C1-C7 알킬 또는 페닐이고;R2는 수소; 비치환 또는 할로겐, C3-C7 사이클로알킬 및 O-R6에서 선택된 치환체에 의해서 치환된 C1-C7 알킬(여기에서 R6는 C1-C4 알킬을 나타낸다); C3-C7 사이클로알킬; 또는 (여기에서 W는 O 또는 S를 나타내고, R7은 수소 또는 C1-C4 알킬을 나타내며, n은 0 내지 3의 정수이다)이며;R3는 수소, 할로겐 또는 C1-C7 알킬이고;R4는 -C(O)OR8이고, R8은 수소, C1-C7 알킬 또는 C3-C7 사이클로알킬이다.
- 제1항에 있어서, 상기 유기용매가 에틸 아세테이트, 디메틸포름아마이드, 아세토니트릴, 아세톤, 테트라하이드로퓨란 및 디클로로메탄으로부터 선택되는 하나 이상인 것을 특징으로 하는 제조 방법.
- 제1항에 있어서, 상기 트리에틸아민을 대신하여 디메틸포름아마이드를 사용하는 것을 특징으로 하는 제조 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280031329.7A CN117255785A (zh) | 2021-04-27 | 2022-04-26 | 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210054152 | 2021-04-27 | ||
KR10-2021-0054152 | 2021-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022231263A1 true WO2022231263A1 (ko) | 2022-11-03 |
Family
ID=83848354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/005927 WO2022231263A1 (ko) | 2021-04-27 | 2022-04-26 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20220147532A (ko) |
CN (1) | CN117255785A (ko) |
WO (1) | WO2022231263A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099206A2 (en) * | 2002-05-21 | 2003-12-04 | Bristol-Myers Squibb Company | Indole compounds useful as impdh inhibitors |
KR20110037883A (ko) * | 2009-10-07 | 2011-04-13 | 주식회사 엘지생명과학 | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
KR20120114174A (ko) * | 2011-04-06 | 2012-10-16 | 주식회사 엘지생명과학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 |
-
2022
- 2022-04-26 WO PCT/KR2022/005927 patent/WO2022231263A1/ko active Application Filing
- 2022-04-26 CN CN202280031329.7A patent/CN117255785A/zh active Pending
- 2022-04-26 KR KR1020220051362A patent/KR20220147532A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099206A2 (en) * | 2002-05-21 | 2003-12-04 | Bristol-Myers Squibb Company | Indole compounds useful as impdh inhibitors |
KR20110037883A (ko) * | 2009-10-07 | 2011-04-13 | 주식회사 엘지생명과학 | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
KR20120114174A (ko) * | 2011-04-06 | 2012-10-16 | 주식회사 엘지생명과학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 |
Non-Patent Citations (2)
Title |
---|
CASCIOFERRO STELLA, ATTANZIO ALESSANDRO, DI SARNO VERONICA, MUSELLA SIMONA, TESORIERE LUISA, CIRRINCIONE GIROLAMO, DIANA PATRIZIA,: "New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity", MARINE DRUGS, vol. 17, no. 1, pages 35, XP055981370, DOI: 10.3390/md17010035 * |
NEETHA MOHAN, AFSINA C. M. A., ANEEJA THAIPPARAMBIL, ANILKUMAR GOPINATHAN: "Recent advances and prospects in the palladium-catalyzed cyanation of aryl halides", RSC ADVANCES, vol. 10, no. 56, 11 September 2020 (2020-09-11), pages 33683 - 33699, XP055981363, DOI: 10.1039/D0RA05960A * |
Also Published As
Publication number | Publication date |
---|---|
KR20220147532A (ko) | 2022-11-03 |
CN117255785A (zh) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6965036B2 (en) | Intermediates for guanidine mimics as factor Xa inhibitors | |
EP2467378B1 (en) | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
JP3256513B2 (ja) | ベンゾイミダゾールシクロオキシゲナーゼ−2阻害剤 | |
CA2654098A1 (en) | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
PL196510B1 (pl) | Pochodne amidowe, ich sole oraz środek farmaceutyczny zawierający takie pochodne lub ich sole | |
IL176912A (en) | Indazole derivatives as inhibitors of hormone-sensitive lipases | |
JP3779725B2 (ja) | 1,2,4−トリアゾール化合物の製造方法及びその中間体 | |
KR20080028516A (ko) | Jnk억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물 | |
CA2707313A1 (en) | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
WO2014176258A1 (en) | Compounds useful as antibiotic tolerance inhibitors | |
CN117402178B (zh) | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 | |
WO2022231263A1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
WO2022231261A1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
AU2018308039B2 (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
WO2022231262A1 (ko) | 잔틴 옥시다아제 저해제의 제조 방법 | |
WO2003011859A2 (en) | Oxazolidinone derivatives as antibacterial agents | |
EP0579059A1 (en) | Pyridazinone derivatives and processes for preparing the same | |
US20090088463A1 (en) | Pyrazoles Useful in the Treatment of Inflammation | |
JP2005041802A (ja) | 1,2,4−トリアゾール化合物の製造方法 | |
US20060189811A1 (en) | Process for producing 1,2,4-triazole compound and intermediate therefor | |
WO2012157977A2 (en) | Manufacturing method of heterocyclic compound | |
CN109608432B (zh) | 作为urat1抑制剂的噻吩类衍生物 | |
AU2004254226B2 (en) | 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same | |
TR2023013434T2 (tr) | Ksanti̇n oksi̇daz i̇nhi̇bi̇törünün sentezi̇ i̇çi̇n ara madde hazirlamaya yöneli̇k yöntem | |
KR100824233B1 (ko) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22796096 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023/013434 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112023000171744 Country of ref document: IT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280031329.7 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22796096 Country of ref document: EP Kind code of ref document: A1 |